Get the latest news, insights, and market updates on TVRD (Tvardi Therapeutics, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
HOUSTON, May 20, 2025--Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company’s Management will participate in the Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways, being held Tuesday, May 27, 2025, and the Jefferies Global Healthcare Conference, being held June 3 – 5, 2025, in New York, N May 20, 2025 - $TVRD
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
HOUSTON, May 13, 2025--Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical- stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the first quarter ended March 31, 2025, and provided a business update. May 13, 2025 - $TVRD
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple